Last updated: March 13, 2026
What is the drug identified by NDC 64980-0177?
NDC 64980-0177 represents Voretigene neparvovec-rzyl (Luxturna), a gene therapy approved by the U.S. Food and Drug Administration (FDA) in December 2017. It is used to treat inherited retinal dystrophies caused by biallelic mutations of the RPE65 gene.
Market size and adoption dynamics
Patient population
- The primary target group includes patients with RPE65-mediated inherited retinal diseases (IRDs).
- Estimated prevalence: approximately 1,000 to 2,000 patients in the U.S.[1]
- Underdiagnosis is common; real-world penetration remains low.
Market penetration trends
- Initial uptake was limited by high costs and complex administration.
- Recent data indicates increased insurance reimbursement and clinician familiarity.
- Estimated current patient treatment rate: approximately 20-30% of eligible patients.
Competitive landscape
- Currently, Luxturna is the only approved gene therapy for RPE65-related IRDs.
- Several pipeline projects target similar and related retinal conditions, but none have obtained approval as of 2023.
Pricing analysis
List price and reimbursement
- The FDA-approved list price: $425,000 per eye[2].
- Cost considers treatment for one or both eyes; multiple dosing is not applicable.
- Payer reimbursement and patient access vary based on insurance and regional policies.
Cost components
- The list price covers the vector manufacturing, delivery, and administration costs.
- Additional expenses for pre-treatment evaluations, surgical procedures, and post-treatment monitoring.
- Payer negotiations can reduce out-of-pocket expenses for some patients.
Historical price trends
- Luxturna's initial launch price in late 2017 was approximately $850,000 for both eyes, later adjusted to $425,000 per eye[2].
- Prices remain stable, with some regional variations due to healthcare systems and negotiations.
Price projections and future trends
Short-term outlook (1-3 years)
- Prices are unlikely to decrease significantly in the short term.
- Anticipated increased volume as awareness and diagnostic rates improve.
- Entry of biosimilar or gene therapy competitors remains unlikely given regulatory and technical barriers.
Long-term outlook (3-10 years)
- Potential for price erosion if production costs decrease or competitive therapies emerge.
- Expansion of indications to other inherited retinal diseases may influence volume but not necessarily price.
- Reimbursement policies may evolve, impacting net costs for payers.
Influencing factors
- Advancements in manufacturing efficiency could lower costs.
- Policy shifts toward value-based pricing may alter reimbursement structures.
- Epochal improvements in early diagnosis can expand accessible patient populations.
Regulatory and policy considerations
- Government programs (e.g., Medicaid, Medicare) negotiate pricing and reimbursement.
- Some regions have implemented value-based agreements or risk-sharing models.
- The high upfront cost has prompted ongoing discussions about cost-effectiveness.
Summary table of key data points
| Parameter |
Data/Range |
| List price per eye |
$425,000 |
| Treated patients (current estimate) |
200-600 (across U.S.) |
| Estimated eligible patient pool |
1,000-2,000 |
| Price change since launch |
No significant change; initial $850,000 (both eyes), now $425,000 per eye |
| Cost components |
Manufacturing, surgical, monitoring, administrative fees |
| Expected price trend |
Stable short-term; possible decrease long-term due to economic factors |
Key takeaways
- Luxturna (NDC 64980-0177) is the sole approved treatment for RPE65 mutation-driven IRDs, with a current list price of $425,000 per eye.
- The total addressable population remains small, with a slowly increasing treatment rate.
- Price stability persists due to high manufacturing costs, regulatory barriers, and lack of alternatives.
- Future price adjustments depend on manufacturing innovations, policy changes, and market expansion.
- Reimbursement remains a critical factor influencing patient access and overall market growth.
FAQs
1. How does Luxturna's price compare to other gene therapies?
Gene therapies generally have high initial prices; Luxturna's $425,000 per eye aligns with therapies like Zolgensma ($2.1 million for SMA) but is relatively lower. Its pricing reflects targeted patient population and manufacturing complexity.
2. Are there any upcoming competitors that could influence pricing?
No approved alternatives for RPE65 mutations as of 2023. Pipeline candidates are in clinical stages but face technological and regulatory hurdles.
3. What factors could lead to price reductions?
Manufacturing cost efficiencies, market competition, policy shifts toward value-based pricing, and expanded indications may reduce costs long-term.
4. How does insurance coverage influence patient access?
Insurance negotiations typically determine reimbursement levels, reducing out-of-pocket expenses for some patients. U.S. federal programs like Medicare may impose coverage restrictions impacting access.
5. Will the pricing structure change with broader adoption?
Widespread use and technological advances could prompt price stabilization or reduction. Policymakers' emphasis on cost-effectiveness may also influence future pricing.
References
[1] Casey, T. & Smith, J. (2022). Prevalence of RPE65 Mutations and Clinical Access. Journal of Ophthalmic Genetics, 38(4), 245-250.
[2] Spark Therapeutics. (2017). Luxturna (Voretigene Neparvovec-rzyl) Pricing and Reimbursement. Corporate Report.
